...
机译:用克里齐替尼治疗的非小细胞肺癌的ALK阳性患者血液生物标志物的价值
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Comprehensive National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
anaplastic lymphoma kinase inhibitor; derived NLR; neutrophils‐to‐lymphocytes rate; non–small cell lung cancer; platelets‐to‐lymphocytes rate;
机译:用克里齐替尼治疗的非小细胞肺癌的ALK阳性患者血液生物标志物的价值
机译:在拉丁美洲肿瘤学实践中,在ALK阳性非小细胞肺癌患者中CNS进展的现实处理模式,存活率和预测
机译:克唑替尼和艾乐替尼序贯治疗ALK重排阳性非小细胞肺癌患者的无进展生存期和总生存期
机译:非小细胞肺癌患者肿瘤表征和预后的辐射瘤生物标志物的发展
机译:表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物:随机对照试验的系统评价。
机译:用ALK抑制剂克唑替尼治疗的ALK阳性非小细胞肺癌患者的药物诱导的估计的肾小球滤过率降低
机译:患者报告的结果和生活质量数据(PROFILE 1007):克唑替尼与先前治疗的ALK阳性晚期非小细胞肺癌患者化疗的随机对照试验